AR031861A1 - Compuesto derivado de naftiridina, composiciones farmaceuticas que lo comprenden y el uso del mismo en la fabricacion de medicamentos - Google Patents
Compuesto derivado de naftiridina, composiciones farmaceuticas que lo comprenden y el uso del mismo en la fabricacion de medicamentosInfo
- Publication number
- AR031861A1 AR031861A1 ARP010103492A ARP010103492A AR031861A1 AR 031861 A1 AR031861 A1 AR 031861A1 AR P010103492 A ARP010103492 A AR P010103492A AR P010103492 A ARP010103492 A AR P010103492A AR 031861 A1 AR031861 A1 AR 031861A1
- Authority
- AR
- Argentina
- Prior art keywords
- 4alkyl
- group
- substituted
- 4alkoxy
- nr5r5a
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 18
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 15
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 11
- -1 -OH Chemical group 0.000 abstract 9
- 229910052794 bromium Inorganic materials 0.000 abstract 9
- 229910052801 chlorine Inorganic materials 0.000 abstract 9
- 229910052731 fluorine Inorganic materials 0.000 abstract 9
- 229910052740 iodine Inorganic materials 0.000 abstract 9
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 7
- 229910052760 oxygen Inorganic materials 0.000 abstract 6
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 5
- 229910052717 sulfur Inorganic materials 0.000 abstract 5
- 125000005842 heteroatom Chemical group 0.000 abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 abstract 1
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuesto derivado de naftiridina de formula (1) o una forma estereoisomérica, mezcla de formas estereoisoméricas o sal del mismo aceptable para el uso farmacéutico, donde: A es un anillo seleccionado entre las formulas (2) y (3); P es O o S; Rb, en cada caso, se selecciona independientemente entre H, F, Cl, Br, I, CN, C1-4alquilo, C1-4alquenilo, C1-4alquinilo, C1-4alquil-O- o C1-4alquil-NH-, NH2; Rc, en cada caso, se selecciona independientemente entre H, C1-4alquilo, C1-4alquenilo y C1-4alquinilo; W es N o CR3; X es N o CR3a; Y es N o CR3b; Z es N o CR3c; teniendo en cuenta que si dos de W, X, Y y Z son N, entonces el resto es distinto de N; R1 se selecciona del grupo: C1-4alquilo sustituido con 0-9 halogenos, ciclopropilo, hidroximetilo y CN; R2 se selecciona del grupo: metilo sustituido con 0-3 R3f, C1-6alquilo sustituido con 0-2 R4, C2-6haloalquilo, C2-5alquenilo sustituido con 0-2 R4, C2-5alquinilo sustituido con 0-1 R4, C3-6cicloalquilo sustituido con 0-2 R3d, fenilo sustituido con 0-2 R3d y un sistema heterocíclico de 3 a 6 miembros que contiene 1-3 heteroátomos seleccionados del grupo: O, N y S, sustituido con 0-2 R3d; R3 se selecciona del grupo: H, C1-4alquilo, -OH, C1-4alcoxilo, OCF3, CF3, F, Cl, Br, I, -(CH2)tNR5R5a, -NO2, -CN, -C(O)R6, -(CH2)tNHC(O)R7, -(CH2)tNHC(O)NR5R5a, -NHSO2R10, -S-C1-4alquilo, -S(O)C1-4alquilo, -S(O)2C1-4alquilo, -SO2NR5R5a, y un anillo heteroaromático de 5 a 6 miembros que contiene 1-4 heteroátomos seleccionados del grupo: O, N y S; R3a se selecciona del grupo: H, C1-4alquilo, -OH, C1-4alcoxilo, OCF3, CF3, F, Cl, Br, I, -(CH2)tNR5R5a, -NO2, -CN, -C(O)R6, -(CH2)tNHC(O)R7, -(CH2)tNHC(O)NR5R5a, -NHSO2R10, -S-C1-4alquilo, -S(O)C1-4alquilo, -S(O)2C1-4alquilo, -SO2NR5R5a, y un anillo heteroaromático de 5 a 6 miembros que contiene 1-4 heteroátomos seleccionados del grupo: O, N y S; como alternativa, R3 y R3a forman juntos -OCH2O-; R3b se selecciona del grupo: H, C1-4alquilo, -OH, C1-4alcoxilo, OCF3, F, Cl, Br, I, -NR5R5a, -NO2, -CN, -C(O)R6, -NHC(O)R7, -NHC(O)NR5R5a, -NHSO2R10, y -SO2NR5R5a; como alternativa, R3a y R3b forman juntos -OCH2O-; R3c se selecciona del grupo: H, C1-4alquilo, -OH, C1-4alcoxilo, OCF3, F, Cl, Br, I, -NR5R5a, -NO2, -CN, -C(O)R6, -NHC(O)R7, -NHC(O)NR5R5a, -NHSO2R10, y -SO2NR5R5a; como alternativa, R3b y R3c forman juntos -OCH2O-; R3d, en cada caso, se selecciona independientemente entre el grupo: H, C1-4alquilo, -OH, C1-4alcoxilo, OCF3, F, Cl, Br, I, -NR5R5a, -NO2, -CN, -C(O)R6, -NHC(O)R7, -NHC(O)NR5R5a, -NHSO2R10, y -SO2NR5R5a; R3e, en cada caso, se selecciona independientemente entre el grupo: H, C1-4alquilo, -OH, C1-4alcoxilo, OCF3, F, Cl, Br, I, -NR5R5a, -NO2, -CN, -C(O)R6, -NHC(O)R7, -NHC(O)NR5R5a, -NHSO2R10, y -SO2NR5R5a; R3f, en cada caso, se selecciona independientemente entre el grupo: H, F, Cl, Br, I, C1-4alquilo, CN, -OH, -O-R11, OCF3, -O(CO)-R13, -OS(O)2C1-4alquilo, -NR12R12a, -C(O)R13, -NHC(O)R13, -SR11, -S(O)R11, -S(O)2R11, -NHSO2R10, y SO2NR12R12a; R4 se selecciona del grupo: H, F, Cl, Br, I, C1-6alquilo sustituido con 0-2 R3e, C3-10carbociclo sustituido con 0-2 R3e, fenilo sustituido con 0-5 R3e, y un sistema heterocíclico de 5 a 10 miembros que contiene 1-3 heteroátomos seleccionados del grupo O, N y S, sustituido con 0-2 R3e; R5 y R5a se seleccionan independientemente del grupo: H y C1-4alquilo; como alternativa, R5 y R5a, junto con el átomo de nitrogeno con el que están unidos, se combinan para formar un anillo de 5 a 6 miembros que contiene 0-1 átomos de O o N; R6 se selecciona del grupo: H, OH, C1-4alquilo, C1-4alcoxilo y NR5R5a; R7 se selecciona del grupo: H, C1-3alquilo y C1-3alcoxilo; R8 se selecciona del grupo: H, (C1-6alquil)carbonilo, C1-6alcoxilo, (C1-4alcoxi)carbonilo, C6-10ariloxilo, (C6-10aril)oxicarbonilo, (C6-10aril)metilcarbonilo, (C1-4alquil)carboniloxi(C1-4alcoxi)carbonilo, C6-10arilcarboniloxi(C1-4alcoxi)carbonilo, C1-6alquilaminocarbonilo, fenilaminocarbonilo, fenil(C1-4alcoxi)carbonilo, y NR5R5a(C1-6alquil)carbonilo; R9 se selecciona entre H, C1-4alquilo, C1-4alquenilo, C1-4alquinilo, (C1-6alquil)carbonilo, C1-6alcoxilo, (C1-4alcoxi)carbonilo, C6-10ariloxilo, (C6-10aril)oxicarbonilo, (C6-10aril)metilcarbonilo, (C1-4alquil)carboniloxi(C1-4alcoxi)carbonilo, C6-10arilcarboniloxi(C1-4alcoxi)carbonilo, C1-6alquilaminocarbonilo, fenilaminocarbonilo, fenil(C1-4alcoxi)carbonilo, y NR5R5a(C1-6alquil)carbonilo; R10 se selecciona del grupo: C1-4alquilo y fenilo; R11 se selecciona entre C1-6alquilo, C1-6haloalquilo, C1-6alquilo sustituido con C3-6cicloalquilo sustituido con 0-2 R3e, C2-6alquenilo, C2-6alquinilo, C3-6carbociclo sustituido con 0-2 R3e; R12 y R12a se seleccionan independientemente entre H, C1-6alquilo, C1-6alquilo sustituido con C3-6cicloalquilo sustituido con 0-2 R3e, y C3-6carbociclo sustituido con 0-2 R3e; como alternativa, R12 y R12a pueden unirse para formar un anillo heterocíclico de 4 a 7 miembros; R13 se selecciona del grupo: H, C1-6alquilo, C1-6haloalquilo, C1-6alcoxilo, C2-6alquenilo, C2-6alquinilo, -O-C2-6alquenilo, -O-C2-6alquinilo, NR12R12a, C3-6carbociclo, y -O-C3-6carbociclo; y t se selecciona entre 0 y 1; que son utiles como inhibidores de la transcriptasa inversa del HIV, y con composiciones farmacéuticas y equipos de diagnostico que los comprenden, y el uso de los mismos en la fabricacion de medicamentos utiles en el tratamiento de infecciones virales o como referente de ensayo o reactivo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21953200P | 2000-07-20 | 2000-07-20 | |
| US28485601P | 2001-04-19 | 2001-04-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR031861A1 true AR031861A1 (es) | 2003-10-08 |
Family
ID=26913986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010103492A AR031861A1 (es) | 2000-07-20 | 2001-07-20 | Compuesto derivado de naftiridina, composiciones farmaceuticas que lo comprenden y el uso del mismo en la fabricacion de medicamentos |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6596729B2 (es) |
| EP (1) | EP1303515A2 (es) |
| JP (1) | JP2004532793A (es) |
| KR (1) | KR20030065454A (es) |
| CN (1) | CN1464878A (es) |
| AR (1) | AR031861A1 (es) |
| AU (1) | AU2001280641A1 (es) |
| BG (1) | BG107439A (es) |
| BR (1) | BR0112606A (es) |
| CA (1) | CA2418194A1 (es) |
| EE (1) | EE200300027A (es) |
| HU (1) | HUP0302862A2 (es) |
| IL (1) | IL153683A0 (es) |
| IS (1) | IS6690A (es) |
| LT (1) | LT2003003A (es) |
| LV (1) | LV13024B (es) |
| MX (1) | MXPA03000434A (es) |
| NO (1) | NO20030248L (es) |
| PL (1) | PL365958A1 (es) |
| SI (1) | SI21139A (es) |
| SK (1) | SK392003A3 (es) |
| WO (1) | WO2002008226A2 (es) |
| YU (1) | YU3203A (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8101629B2 (en) | 2001-08-13 | 2012-01-24 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
| US7638522B2 (en) | 2001-08-13 | 2009-12-29 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| TW200306192A (en) | 2002-01-18 | 2003-11-16 | Bristol Myers Squibb Co | Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors |
| AR039540A1 (es) | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
| BR0313545B1 (pt) * | 2002-08-09 | 2021-07-27 | Janssen Pharmaceutica Nv | processos para a preparação de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrila |
| CA2513527C (en) | 2003-02-07 | 2012-08-14 | Janssen Pharmaceutica N.V. | Pyrimidine derivatives for the prevention of hiv infection |
| AP2006003791A0 (en) | 2004-05-17 | 2006-10-31 | Tibotec Pharm Ltd | 1-Heterocyclyl-1,5-dihydro-pyridoÄ3,2-BÜindol-2-ones |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3700673A (en) * | 1971-02-12 | 1972-10-24 | Morton Norwich Products Inc | 3-4-dihydrobenzo(b) (1,7)naphthyridin-1(2h)-ones |
| GB9023289D0 (en) | 1990-10-25 | 1990-12-05 | Ici Plc | Herbicides |
| IL102764A0 (en) | 1991-08-16 | 1993-01-31 | Merck & Co Inc | Quinazoline derivatives,and pharmaceutical compositions containing them |
| AU2436792A (en) * | 1991-08-16 | 1993-03-16 | Merck & Co., Inc. | Quinazoline derivatives as inhibitors of hiv reverse transcriptase |
| DE4320347A1 (de) | 1993-06-19 | 1994-12-22 | Boehringer Mannheim Gmbh | Quinazolin-Derivate und diese enthaltende Arzneimittel |
| AU1046895A (en) | 1993-11-05 | 1995-05-23 | Merck & Co., Inc. | New quinazolines as inhibitors of hiv reverse transcriptase |
| DE4344452A1 (de) | 1993-12-24 | 1995-06-29 | Hoechst Ag | Aza-4-iminochinoline, Verfahren zu ihrer Herstellung und ihre Verwendung |
| ID18046A (id) | 1996-08-20 | 1998-02-19 | Takeda Chemical Industries Ltd | Senyawa siklik campuran, pembuatan dan penngunaannya. |
| WO1998014436A1 (en) | 1996-10-02 | 1998-04-09 | Dupont Pharmaceuticals Company | 4,4-disubstituted-1,4-dihydro-2h-3,1-benzoxazin-2-ones useful as hiv reverse transcriptase inhibitors and intermediates and processes for making the same |
| HRP980143A2 (en) | 1997-04-09 | 1999-02-28 | Soo Sung Ko | 4,4-disubstituted-3,4-dihydro-2 (1h)-quinazolinones useful as hiv reverse transcriptase inhibitors |
| US6593337B1 (en) | 1999-10-19 | 2003-07-15 | Bristol-Myers Squibb Pharma Company | Tricyclic compounds useful as HIV reverse transcriptase inhibitors |
-
2001
- 2001-07-19 US US09/908,995 patent/US6596729B2/en not_active Expired - Lifetime
- 2001-07-20 AR ARP010103492A patent/AR031861A1/es unknown
- 2001-07-20 EP EP01959047A patent/EP1303515A2/en not_active Withdrawn
- 2001-07-20 HU HU0302862A patent/HUP0302862A2/hu unknown
- 2001-07-20 SI SI200120050A patent/SI21139A/sl not_active IP Right Cessation
- 2001-07-20 WO PCT/US2001/022827 patent/WO2002008226A2/en not_active Application Discontinuation
- 2001-07-20 AU AU2001280641A patent/AU2001280641A1/en not_active Abandoned
- 2001-07-20 CA CA002418194A patent/CA2418194A1/en not_active Abandoned
- 2001-07-20 EE EEP200300027A patent/EE200300027A/xx unknown
- 2001-07-20 SK SK39-2003A patent/SK392003A3/sk unknown
- 2001-07-20 IL IL15368301A patent/IL153683A0/xx unknown
- 2001-07-20 CN CN01815629A patent/CN1464878A/zh active Pending
- 2001-07-20 MX MXPA03000434A patent/MXPA03000434A/es unknown
- 2001-07-20 BR BR0112606-7A patent/BR0112606A/pt not_active Application Discontinuation
- 2001-07-20 KR KR10-2003-7000800A patent/KR20030065454A/ko not_active Application Discontinuation
- 2001-07-20 PL PL01365958A patent/PL365958A1/xx not_active Application Discontinuation
- 2001-07-20 YU YU3203A patent/YU3203A/sh unknown
- 2001-07-20 JP JP2002514132A patent/JP2004532793A/ja active Pending
-
2003
- 2003-01-06 BG BG107439A patent/BG107439A/bg unknown
- 2003-01-15 LT LT2003003A patent/LT2003003A/xx not_active Application Discontinuation
- 2003-01-17 IS IS6690A patent/IS6690A/is unknown
- 2003-01-17 NO NO20030248A patent/NO20030248L/no not_active Application Discontinuation
- 2003-02-18 LV LVP-03-16A patent/LV13024B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| YU3203A (sh) | 2006-01-16 |
| SK392003A3 (en) | 2003-10-07 |
| IL153683A0 (en) | 2003-07-06 |
| US6596729B2 (en) | 2003-07-22 |
| KR20030065454A (ko) | 2003-08-06 |
| NO20030248D0 (no) | 2003-01-17 |
| EP1303515A2 (en) | 2003-04-23 |
| WO2002008226A3 (en) | 2002-06-20 |
| BR0112606A (pt) | 2004-06-29 |
| EE200300027A (et) | 2004-10-15 |
| CN1464878A (zh) | 2003-12-31 |
| SI21139A (sl) | 2003-08-31 |
| CA2418194A1 (en) | 2002-01-31 |
| AU2001280641A1 (en) | 2002-02-05 |
| US20020107261A1 (en) | 2002-08-08 |
| IS6690A (is) | 2003-01-17 |
| WO2002008226A2 (en) | 2002-01-31 |
| NO20030248L (no) | 2003-03-17 |
| LT2003003A (en) | 2003-11-25 |
| MXPA03000434A (es) | 2003-06-24 |
| HUP0302862A2 (hu) | 2003-12-29 |
| JP2004532793A (ja) | 2004-10-28 |
| BG107439A (bg) | 2003-09-30 |
| LV13024B (en) | 2003-10-20 |
| PL365958A1 (en) | 2005-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR040400A1 (es) | Tratamiento de enfermedades mediadas por quimiocinas | |
| AR056875A1 (es) | Ligandos del receptor vaniloide y su aplicacion para la fabricacion de medicamentos | |
| AR080676A1 (es) | Compuestos de sililo triciclicos fusionados y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
| AR031861A1 (es) | Compuesto derivado de naftiridina, composiciones farmaceuticas que lo comprenden y el uso del mismo en la fabricacion de medicamentos | |
| AR081848A1 (es) | Inhibidores de la proteina ns5a del vhc | |
| HRP20191754T1 (hr) | Spojevi i postupci za antivirusno liječenje | |
| AR038863A1 (es) | Uso de un inhibidor de garft y/o de aicarft y de un agente antitoxico para preparar un medicamento para destruir selectivamente celulas mtap-deficientes de un mamifero | |
| AR053710A1 (es) | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos | |
| AR036375A1 (es) | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos | |
| AR049126A1 (es) | Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing. | |
| AR049300A1 (es) | Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos | |
| AR082763A1 (es) | Derivados de piperidinona como inhibidores mdm2 para el tratamiento de cancer | |
| AR035548A1 (es) | Compuestos organicos | |
| AR077267A1 (es) | Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes. | |
| AR055669A1 (es) | Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales. | |
| AR045218A1 (es) | Aminas ciclicas inhibidoras de bace-1 que poseen una benzamida sustituyente; composiciones farmaceuticas que las contienen y su uso en la fabricacion de medicamentos para tratar enfermedades cognitivas o neurodegenerativas. | |
| AR046600A1 (es) | Diazaespiroalcanos y su uso como tratamiento para enfermedades mediadas por ccr8 | |
| CO5290258A1 (es) | Derivados de fenilheteroalquilaminas, proceso para su prepracion y composiciones farmaceuticas que contienen dichos derivados | |
| ES2623982T3 (es) | Compuestos heterocíclicos de unión a receptor de quimiocina con eficacia potenciada | |
| AR051753A1 (es) | Metodos para preparar compuestos de indazol | |
| AR031853A1 (es) | Derivados biciclicos de amino acidos con puente aza, proceso para preparar un intermediario, composicion farmaceutica que los comprende y uso de tales derivados en la fabricacion de un medicamento para tratar trastornos mediados por integrina | |
| CO6220931A2 (es) | Inhibidores de serina proteasas para el tratamiento de infecciones de vhc | |
| AR058587A1 (es) | Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos | |
| AR056511A1 (es) | Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4 | |
| ES2606197T3 (es) | Moduladores pirrolidina de GPR40 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |